Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, multicentre, international Registry of male and female patients newly diagnosed with Atrial Fibrillation and treated with Rivaroxaban

Next Previous
Trial Profile

Prospective, multicentre, international Registry of male and female patients newly diagnosed with Atrial Fibrillation and treated with Rivaroxaban

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Jul 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms RIVER
  • Sponsors Bayer

Most Recent Events

  • 10 Mar 2016 Accrual to date is 645% according to the United Kingdom Clinical Research Network record.
  • 13 Dec 2015 Accrual to date is 205% according to the United Kingdom Clinical Research Network record.
  • 15 Nov 2015 Accrual to date is 60% according to the United Kingdom Clinical Research Network record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top